Drugs / XmAb808
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07593092 | Jun 2026 → Dec 2028 expected | ovarian cancer | Xencor, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05585034 | Dec 2022 → May 2025 | castration-resistant prostate carcinoma, clear cell renal carcinoma, colorectal cancer, head and neck squamous cell carcinoma +5 | Xencor, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XmAb808 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05585034 ↗ |
| Modality | Monoclonal antibody | “Monoclonal bispecific antibody” NCT05585034 ↗ |
| Route | Intravenous | “intravenous (IV) administration of XmAb808” NCT05585034 ↗ |